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A B S T R A C T
Background
Fatigue is a common and disabling symptom in people with a primary brain tumour (PBT). The effectiveness of interventions for
treating clinically significant levels of fatigue in this population is unclear.
Objectives
To assess the effectiveness and safety of pharmacological and non-pharmacological interventions for adults with PBT and high levels
of fatigue.
Search methods
In March 2016, we searched the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO and CINAHL and
checked the reference lists of included studies. We also searched relevant conference proceedings, searched for ongoing trials via
ClinicalTrials.gov and contacted major co-operative groups with trials in this area.
Selection criteria
We included randomised controlled trials (RCTs) that investigated any pharmacological or non-pharmacological intervention in adults
with PBT and fatigue, where fatigue was the primary outcome measure. We restricted inclusion specifically to studies that enrolled
only participants with clinically significant levels of fatigue.
Data collection and analysis
Three review authors (JD, SYK, DC) independently evaluated search results, extracted data from selected studies and carried out a bias
risk assessment. We extracted data on fatigue, cognition, mood, quality of life and adverse events outcomes.
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Main results
We identified nine studies. We excluded eight of these as they did not restrict participation to people with high fatigue. The single
eligible trial investigated the use of modafinil compared to placebo. Although this study found a significant improvement over time in
the primary outcome of fatigue, the improvement occurred after both modafinil and placebo with no significant difference in response
between the two groups. The included trial did not reach its planned recruitment target and therefore may not, in practice, have been
adequately powered to detect a difference. The trial was at a low risk of bias across most areas. There was an unclear risk of bias related
to the use of mean imputation because the investigators did not analyse the impact of imputation on the results.
Authors’ conclusions
There was insufficient evidence to draw reliable and generalisable conclusions regarding potential effectiveness or harm of any phar-
macological or non-pharmacological treatments for fatigue in people with PBT. More research is needed on how best to treat people
with brain tumours with high fatigue.
P L A I N L A N G U A G E S U M M A R Y
Interventions for the management of fatigue in adults with a primary brain tumour
Background
A primary brain tumour (PBT) is a cancer that began in the brain rather than spread from other parts of the body. Fatigue (tiredness) is
common in people with a PBT. This may be due to the tumour, its treatment or to the use of other medicines such as antiepileptic drugs
(which are used to treat epilepsy seizures). It may also occur with other symptoms such as sleep disturbance, thinking problems and
emotional distress. Treatments to help manage fatigue may improve a person’s quality of life, their ability to tolerate cancer treatment
(which themselves are associated with fatigue), and their ability to carry out social and day-to-day activities.
Study characteristics
In March 2016, we searched five medical databases. We found one clinical trial that was eligible for inclusion; the trial investigated the
medicine modafinil in 37 adults with PBT and high levels of fatigue. People in the study received six weeks of modafinil followed by a
one-week washout period and six further weeks of placebo, or vice versa. The washout period aims to allow time for any effects of the
first treatment to wear off before the new one gets started.
Key findings
The one included trial found no evidence of a difference between modafinil and placebo in treating fatigue. It is possible that this could
be due to the trial not reaching its planned number of participants. Several other studies investigated the management of fatigue too,
but in these studies high fatigue was not essential for participation. We do not currently know whether any treatments are effective in
the management of people with PBT and high fatigue.
Quality of the evidence
With only one included trial, the overall quality of evidence was low. More high-quality studies are needed that enrol adults with BPT
and high fatigue.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M odafinil compared with placebo for fatigue in people with a primary brain tumour
Patient or population: people with a primary brain tumour
Settings: hospital, outpat ient
Intervention: modaf inil
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo M odafinil
Fatigue - concentration
problems
Sub-scale f rom Check-
list Individual Strength
Scale f rom: 0 to 35
(follow-up: 6 weeks)
The mean concentra-
t ion problem score
ranged across control
groups f rom 15.91 to
23.91 points
The mean concentra-
t ion problem score in
the intervent ion groups
was 1.06 lower
(-3.18 to 1.06 lower)
- 37 (1) ⊕⊕©©
low
Higher scores indicate
a high level of concen-
trat ion problems
Fatigue - reduced mo-
tivation
Sub-scale f rom Check-
list Individual Strength
Scale f rom: 0 to 28
(follow-up: 6 weeks)
The mean reduced mo-
t ivat ion score ranged
across control groups
f rom 10.22 to 19.48
points
The mean reduced mo-
t ivat ion score in the in-
tervent ion groups was
0.48 lower
(-2.93 to 1.97 lower)
- 37 (1) ⊕⊕©©
low
Higher scores indicate
lower motivat ion
Fatigue - reduced ac-
tivity
Sub-scale f rom Check-
list Individual Strength
Scale f rom: 0 to 21
(follow-up: 6 weeks)
The mean reduced
act ivity score ranged
across control groups
f rom 3.84 to 21.34
points
The mean reduced ac-
t ivity score in the inter-
vent ion groups was 1.
01 lower
(-5.64 to 3.62 lower)
- 37 (1) ⊕⊕©©
low
Higher scores indicate
lower act ivity
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Fatigue - fatigue sever-
ity
Sub-scale f rom Check-
list Individual Strength
Scale f rom: 0 to 56
The mean fat igue
severity score ranged
across control groups
f rom 34.06 to 36.22
points
The mean fat igue
severity score in the in-
tervent ion groups was
0.22 lower
(-0.79 to 0.35 lower)
- 37 (1) ⊕⊕©©
low
High scores indicate a
high level of fat igue
Adverse events
(follow-up: 6 weeks)
Low- risk population RR 2.79, 95% CI 0.59 to
13.16
37 (1) ⊕⊕©©
low
-
- 30 per 100
(1 to 180)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
4
In
te
rv
e
n
tio
n
s
fo
r
th
e
m
a
n
a
g
e
m
e
n
t
o
f
fa
tig
u
e
in
a
d
u
lts
w
ith
a
p
rim
a
ry
b
ra
in
tu
m
o
u
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Fatigue is one of the most common symptoms experienced by
people with cancer. The reported prevalence rates for cancer-re-
lated fatigue in the clinical trial setting is in the range of 70%
to 80% (Lawrence 2004; Lovely 1999). Cancer-related fatigue is
“a distressing, persistent, subjective sense of physical, emotional,
and/or cognitive tiredness or exhaustion related to cancer that is
not proportional to recent activity and interferes with usual func-
tioning” (NCCN 2014). Fatigue is also a common adverse effect
of cancer treatment (Roscoe 2002), occurs across various cancer
types (Stone 2000), and persists in disease-free survivors (Servaes
2007). As the scientific knowledge about cancer-related fatigue
expands, there is increasing recognition on the importance of its
effective management (Goedendorp 2009).
Prevalence of fatigue in primary brain tumours
Prevalence estimates suggest that as in other cancer populations,
fatigue is an extremely common problem in people with a pri-
mary brain tumour (PBT). In one study, 96% of people with
high-grade glioma reportedmoderate or severe fatigue (Fox 2007).
Studies enrolling mixed high-grade and low-grade tumour pop-
ulations estimated that up to 42% of people with PBT had fa-
tigue (Pelletier 2002). Fatigue remains troublesome throughout
the course of survivorship, from the 12 months following PBT
diagnosis (Molassiotis 2010), to more than eight years after diag-
nosis (Struik 2009). Fatigue in PBT has been studied both as a
primary outcome (Armstrong 2010; Lovely 1999), and as a sec-
ondary outcome related to symptoms such as depression (Rooney
2011), poor quality of life (Kvale 2009), and sleep-wake distur-
bances (Miaskowski 2011).
Associated clinical variables
Fatigue in the setting of PBT has multiple potential causes includ-
ing primary treatments of the tumour, secondary symptomatic
treatments, and the physical and emotional consequences of the
diagnosis (Armstrong 2012). Up to 80% of people undertaking
cranial radiotherapy report fatigue (Lovely 1999). Although it is
rarely the only possible cause, radiotherapy in particular may exac-
erbate fatigue by endocrine (hormone) dysfunction when the irra-
diated area encroaches upon the hypothalamus or pituitary gland.
The hypothalamic-pituitary-adrenal axis feedback system is re-
sponsible for controlling the secretion of many hormones that reg-
ulate many body processes, including sleep (Arlt 1997; Taphoorn
1995).
Fatigue is also a recognised adverse effect of many medications
that may be taken by people with PBT, including chemotherapy,
anticonvulsant drugs (Lu 2009; Maschio 2008; Struik 2009), and
corticosteroids (Drappatz 2007; Hinds 2007). Fatigue is further
associated with sleep disturbance, cognitive complaints, depres-
sion and anxiety (Armstrong 2010; Fox 2007; Pelletier 2002), and
this cluster of symptoms may significantly influence people’s qual-
ity of life (Fox 2007). Symptom clustering can make the presence
of fatigue difficult to distinguish from other symptoms such as
depression (Rooney 2011).
The relationship between histological tumour grade and fatigue
remains unclear. Some authors find fatigue to be more common in
high-grade than in low-grade tumours (Salo 2002), whereas other
authors do not (Armstrong 2010; Pelletier 2002). Regardless, the
wide range of possible causes suggest that fatigue is best investi-
gated as a multifactorial symptom alongside these other associated
issues (Armstrong 2010).
Methods of measuring fatigue
Many tools have been developed to measure fatigue in people with
cancer (Jean-Pierre 2007); each instrument relies on subjective
patient report. The Brief Fatigue Inventory (Mendoza 1999) has
been used in several studies including brain tumour correlation
studies (Kim2012), and clinical trials (Gehring 2012).Othermea-
surement tools validated for use in cancer include the Functional
Assessment of Cancer Therapy - Fatigue (Yellen 1997), the Can-
cer-Related Fatigue Distress Scale (Holley 2000), the Fatigue As-
sessment Questionnaire (Glaus 1998), the Revised Piper Fatigue
Scale (Piper 1998), and the Multidimensional Fatigue Symptom
Inventory (Stein 2004). Several general and brain tumour-spe-
cific quality of life measures also assess fatigue, such as the Func-
tional Assessment of Cancer Therapy - Brain (FACT-Br) (Cella
1993), the MD Anderson Symptom Inventory Brain Tumour
Module (MDASI-BT) (Armstrong 2006), the European Orga-
nization of Research and Treatment Quality of Life Question-
naire-C30 (EORTC QLQ-C30) (Ringdal 1993), and the World
Health Organization Quality of Life assessment (WHOQOL)
(WHOQOL Group 1995). With many different tools available
caution is needed when synthesising data in a systematic review
or meta-analysis.
Description of the intervention
In this review, we included pharmacological and non-pharmaco-
logical interventions for fatigue in PBT.We defined pharmacolog-
ical interventions as a drug, given by any route at any therapeutic
dose, with the primary intention of treating fatigue. Such drugs
could include psychostimulants and antidepressants. We defined
non-pharmacological interventions and general strategies as any
psychological or behavioural treatment with the primary aim of
improving fatigue in PBT. These interventions could, for example,
include physical activity, cognitive or behavioural therapies and
psychosocial interventions.
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How the intervention might work
Studies have started to explore interventions aimed at improv-
ing and alleviating symptoms of fatigue (e.g. Cramp 2012;
Goedendorp 2009; Minton 2013).
Pharmacological interventions
Pharmacological treatmentsmight reduce fatigue by acting on crit-
ical neurotransmitter pathways. For example, the central nervous
system stimulant, methylphenidate, could enhance neural signal
processing by increasing concentrations of dopamine and nora-
drenaline (norepinephrine) (Volkow 2002). Similarly, the central
nervous system stimulant, modafinil, may enhance the effect of
dopamine, associated with wakefulness and motivation (Young
2010).
Non-pharmacological interventions
Psychological interventions may improve fatigue by introducing
and reinforcing adaptive coping strategies (Armstrong 2012). This
approach can be effective through the use of cognitive therapy,
which identifies negative or maladaptive thoughts/beliefs, chal-
lenges them and replaces them with more helpful and realistic al-
ternatives (Beck 1979).
These strategies could be used alongside behavioural interventions
such as exercise. Exercise may improve fatigue in people with PBT
by increasing mental and physical stamina. A reduction in fatigue
could be achieved through a balance between activity and rest
(Winningham 1992). Excessive rest could promote muscle wast-
ing and decreasing cardiorespiratory fitness, adding to the per-
ception of fatigue (Dimeo 2001). By increasing functional capac-
ity, exercise could reduce fatigue (NCCN 2014), while alleviating
anxiety and improving mood (Dimeo 2001).
Why it is important to do this review
Fatigue is consistently the single most frequently reported symp-
tom in studies of people with PBT. Therefore, there is a press-
ing need to search for trials in this area systematically to generate
a high-quality review of interventions for fatigue in people with
PBT. With survival times for low-grade PBT typically measured
in years, and survival times for certain subgroups of people with
high-grade PBT gradually increasing, there is great potential ben-
efit in establishing which interventions are effective for fatigue.
Effective interventions could improve quality of life, yet themulti-
factorial nature of fatigue (potentially including neuroendocrine,
neuroimmune and psychosocial causes) makes it a symptom that
can be particularly difficult to treat (Bowe 2012).
A clear synthesis of the evidence for the effectiveness of managing
fatigue in PBT is currently lacking. This review will answer a clin-
ically useful research question: what are the effective interventions
for managing fatigue in adults with a PBT?
O B J E C T I V E S
To assess the effectiveness and safety of pharmacological and non-
pharmacological interventions for adults with PBT and high levels
of fatigue.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of any interven-
tion for the management of fatigue in adults with PBT, in which
fatigue was (one of ) the primary or secondary therapeutic out-
come(s). Due to the prediction that there may currently be few
RCTs that satisfy the inclusion criteria, we planned to include a
narrative description of relevant excluded RCTs in the Excluded
studies section. This was intended to provide valuable information
about interventions that may warrant further investigation.
Types of participants
We included studies that evaluated the effect of interventions on
adults (aged 18 years or older) with high self reported fatigue (de-
fined by a pre-established cut-off using a questionnaire, validated
measure, or presence/absence report), and with a histological di-
agnosis of PBT at any stage in their illness. Following discussion,
we excluded studies that recruited non-fatigued participants. We
reasoned that the clinically relevant question of how to treat high
fatigue required a strict focus on studies that enrolled people with
high fatigue.
Types of interventions
Pharmacological interventions
For pharmacological interventions, we aimed to investigate the
effectiveness of any drug, given by any route and at any therapeutic
dose, with the intention of treating fatigue in PBT. For ethical
reasons, RCTs of psychoactive drugs may not necessarily include
a placebo arm. In order to increase the relevance of the review, we
included studies without a placebo arm, provided that the study
randomly allocated participants to a control group (e.g. treatment
as usual, another active drug or allocation to a waiting list).
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Non-pharmacological interventions
For psychological interventions, we aimed to study any cognitive
treatment given with the aim of improving fatigue in PBT. For
behavioural interventions, we aimed to investigate the effectiveness
of any behavioural or social treatment given for the improvement
of fatigue in PBT; this may have included exercise and energy
management techniques. We included RCTs in which the control
group was allocated to treatment as usual or to a waiting list.
Types of outcome measures
Primary outcomes
• Fatigue at study endpoint.
Due to potential differences in effectiveness endpoints between
the different interventions, we aimed to analyse both short-term
and long-term effects of these interventions, where the data were
available.
High fatigue may be summarised categorically as ’present’ or ’ab-
sent’ (e.g. in response to a clinical interview), or else quantified
ordinally on a rating scale assessing fatigue using cut-offs defined
by the measure used. Such rating scales can be specific to fatigue,
or may assess fatigue as part of a wider symptom screen (e.g. as part
of quality of life). We included studies in which fatigue was self
reported using any validatedmethod. Due to the subjective nature
of fatigue, we did not include studies using clinician-reported or
relative- or carer-reported measures, because these may not be a
true reflection of the person’s symptoms.
If fatigue was measured by a rating scale, we aimed to quantify
its improvement with respect to the recommended scale threshold
for ’caseness’. If possible, we also aimed to record the total number
of people reaching ’non-fatigued’ status.
Secondary outcomes
• General functioning, including quality of life measurements
(e.g. Health Related Quality of Life questionnaire), and
depression (e.g. Hospital Anxiety and Depression Scale) and
cognitive outcomes (e.g. Addenbrooke’s Cognitive Examination -
Revised) according to validated measures.
• Overall survival (OS) and progression-free survival (PFS).
• Adverse events as described by Katz 2012. Adverse event
occurrence: clinical adverse events; any serious adverse event as
defined by any medical occurrence in any participant that
resulted in a dose reduction or treatment discontinuation, which
did not necessarily have causal relationship with the treatment.
The International Conference on Harmonisation Guidelines
defines serious adverse events as any event that may jeopardise
the person or require an intervention to prevent it (ICH-GCP
1997). This includes any important medical event that: was life-
threatening, led to death, resulted in significant or persistent
disability or congenital anomaly/birth defect, or required
inpatient hospitalisation or prolongation of existing
hospitalisation, which may have jeopardised the person or
required intervention to prevent it.
If possible and appropriate, we aimed to combine outcomes in
a meta-analysis. The secondary outcomes were not criteria for
eligibility for this review, but were outcomes that we noted and
reviewed.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (Issue 2, 2016), MEDLINE (1950 toMarch 2016),
EMBASE (1980 to March 2016), PsycINFO (1974 to March
2016) and CINAHL (1982 to March 2016), (Appendix 1, Ap-
pendix 2; Appendix 3; Appendix 4). We did not apply language
or date restrictions in any of the searches.
Searching other resources
Unpublished and grey literature
We searched online databases of registered clinical trials to identify
ongoing trials. We also approached the major co-operative trial
groups active in this area.
Handsearching
We handsearched the reference lists of included studies and pre-
vious systematic reviews. We handsearched the latest journal and
conferencematerials in 2014 and 2015 from the following sources:
• Annual Meeting of the European Society of Medical
Oncology (ESMO);
• Annual meeting of the European Association of Neuro-
Oncology (EANO);
• Annual meeting of the World Federation of Neuro-
Oncology (WFNO);
• Annual Meeting of the American Society of Clinical
Oncology (ASCO);
• Annual Meeting of the Society for Neuro-Oncology (SNO);
• Annual Meeting of the Society for Behavioral Medicine
(SBM);
• Annual Meeting of the American Psychosocial Oncology
Society (APOS);
• Annual Meeting of the International Psycho-Oncology
Society (IPOS);
• Annual Meeting of the Multinational Association of
Supportive Care in Cancer (MASCC).
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Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searches to the reference management database EndNote. We re-
moved duplicates and three review authors (JD, SYK, DC) inde-
pendently examined the remaining references. The review authors
were not blinded to the authors or affiliations of the studies. We
excluded those studies that clearly did not meet the inclusion cri-
teria and we obtained copies of the full text of potentially relevant
references. Three review authors (JD, SYK, DC) independently
assessed the eligibility of retrieved papers. We resolved disagree-
ments by discussion and documented the reasons for exclusion.
Data extraction and management
Data extraction
For included trials, we extracted data as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). Three review authors (JD, SYK, DC) independently ex-
tracted data onto a data extraction form specially designed for the
review.
We extracted data on the following:
• article details (author, year of publication, journal citation,
country and language);
• intervention (characteristics, e.g. drug name, dose and
duration);
• study design and methodology (including inclusion and
exclusion criteria, assignment process and timing of
measurements);
• population demographics (e.g. age, gender and marital
status) and total number involved;
• details of participants’ health status (including tumour
pathology and treatment details).
• dichotomous and continuous outcome measures (fatigue,
cognitive functioning, quality of life, depression and adverse
events);
• risk of bias.
Where possible, we extracted all data relevant to an intention-
to-treat analysis, in which participants are analysed in groups to
which they are assigned.
Data management
We collated and entered data into Review Manager 5 (RevMan
2014).
Continuous data
For continuous outcomes (e.g. fatigue scales, cognitive tests and
measures, depression measures, quality of life measures), we ex-
pressed the treatment effect as a mean difference (MD) with 95%
confidence interval (CI). We extracted post-intervention data to
calculate the MD, the final value and standard deviation (SD) of
the outcome of interest, and the number of participants assessed
in each treatment arm at the end of follow-up. If more than one
trial was eligible, and trials measured outcomes on the same scale,
we aimed to express treatment effect as an MD, with 95% CIs.
If trials measured outcomes on different scales, we aimed to ex-
press treatment effect as standardised mean differences (SMDs)
between treatment arms, with 95% CIs.
Dichotomous data
For dichotomous outcomes (e.g. high or low fatigue), we extracted
the number of participants in each treatment armwho experienced
the outcome of interest, at baseline and at study endpoint. We
aimed to dichotomise fatigue using validated thresholds.We noted
the time points at which outcomes were collected and reported.
Assessment of risk of bias in included studies
We assessed the risk of bias in included studies using Cochrane’s
’Risk of bias’ tool (Higgins 2011). This included assessment of:
• selection bias: random sequence generation and allocation
concealment;
• performance bias: blinding of participants and personnel
(participants and treatment providers);
• detection bias: blinding of outcome assessment;
• performance bias: participants received similar care out
with the intervention they received;
• attrition bias: incomplete outcome data;
• reporting bias: selective reporting of outcomes
• other possible sources of bias.
See Appendix 5 for full description of each risk of bias area. Three
review authors (JD, SYK, DC) applied the ’Risk of bias’ tool inde-
pendently and resolved differences by discussion. We summarised
results in a ’Risk of bias’ summary table.We aimed to interpret the
results of any meta-analyses in light of the findings with respect
to risk of bias. We judged and reported all bias criteria in terms of
’low’, ’high’ or ’unclear’ risk of bias. We classified criteria as having
an ’unclear’ risk of bias where insufficient information was pro-
vided, or when there was uncertainty over the potential for bias.
We contacted authors to clarify uncertainties, if possible. It was
noted that blinding may not have been possible for all treatment
comparisons, particularly with respect to any non-pharmacologi-
cal interventions such as exercise.
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Measures of treatment effect
For continuous data, we used MDs or SMDs as appropriate. For
dichotomous data, we calculated the risk ratio (RR).
Dealing with missing data
Wedidnot imputemissing outcomedata for the primary outcome.
For the primary outcome, if data were missing, or only imputed
data were reported, we contacted trial authors to request data on
the outcomes among participants who were assessed.
We included details of missing data in the narrative summary and
’Risk of bias’ table, and statedwhether authors examined the extent
to which the missing data could have altered the results of the
review.
Assessment of heterogeneity
Assessment of heterogeneity was not possible because only one
trial was eligible for inclusion in the review.
We planned to assess heterogeneity between studies by visual in-
spection of forest plots (including the presence of outliers and a
poor overlap of CIs), and by a formal statistical test of the signifi-
cance of the heterogeneity (Deeks 2001). We planned to investi-
gate and report heterogeneity according to Higgins 2011.
Assessment of reporting biases
Three review authors (JD, SYK, DC) reviewed and recorded re-
porting biases.
We aimed to examine funnel plots to assess the potential for small-
study effects, such as publication bias, if themeta-analysis included
more than 10 trials.
Data synthesis
We planned to pool data for meta-analysis using Review Manager
5 if studies were comparable with respect to participants, inter-
ventions and outcomes (RevMan 2014). We intended to combine
studies at the level of the intervention itself (e.g. psychostimulant,
cognitive behavioural therapy, exercise) rather than broad cate-
gories (e.g. pharmacological, psychological, behavioural). Had a
meta-analysis been possible, we planned to carry it out as follows.
• We planned to pool the MDs between the treatment arms
at the end of follow-up if all trials measured the outcome on the
same scale and at the same primary study endpoint, otherwise we
planned to pool SMDs.
• For dichotomous data, we intended to use risk ratios (RRs)
and 95% CIs.
• We intended to use random-effects models with inverse
variance weighting for all meta-analyses, with 95% CIs
(DerSimonian 1986).
• For dichotomous data for adverse events, we planned to
pool RRs.
• We intended to note the time points at which outcomes
were collected and reported.
However, data synthesis was not possible as only one trial was
eligible for inclusion in the review.
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analyses comparing changes
in scale score studies using identical scales, where appropriate.
We also intended to perform subgroup analyses according to
World Health Organization (WHO) tumour grade (low grade/
high grade) and interventions delivered only during treatment/
only during follow-up.
However, subgroup analysis and investigation of heterogeneity was
not possible because only one trial was eligible for inclusion in the
review.
Sensitivity analysis
We planned to involve all review authors in determining whether
sensitivity analysis would be required, under the guidance of
Higgins 2011.
We intended to consider the following factors as possible sources
of heterogeneity across studies.
• Differing study quality (high or low levels of risk of bias).
• Different classes of drugs.
• Dosage or scheduling differences.
We planned to identify additional possible types of sensitivity anal-
yses during the conduct of the review.
However, sensitivity analysis was not carried out as only one trial
was eligible for inclusion in the review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies tables.
Results of the search
Figure 1 shows details of the search.
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Figure 1. Study flow diagram.
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We found 4941 citations when searching electronic databases and
following de-duplication of the results. The results were narrowed
to nine articles upon screening of the titles and abstracts. One trial
was eligible for inclusion in the review (Boele 2013). Eight studies
did not meet our inclusion criteria for analysis due to the lack of
high self reported fatigue as a necessary inclusion criterion (Butler
2007; Gehring 2009; Gehring 2012; Kaleita 2006; Lee 2014;
Locke 2008; Shaw 2006; Shaw 2015).We identified no additional
studies when searching conference proceedings and the reference
list of the single included trial. We identified no additional studies
when contacting experts in the field. There was one ongoing trial
(Umphrey 2013).
Included studies
For detailed information see Characteristics of included studies
table.
We found one eligible trial. Boele 2013 investigated the use of
modafinil in treating fatigue in people with PBT compared with
a placebo intervention.
Participant demographics
The study recruited 37 of the estimated 64 required participants
from three neuro-oncology centres in The Netherlands. Their
mean age was 48.16 years (SD 12.02). Participants had a menin-
gioma (32.4%), low-grade glioma (37.8%) or high-grade glioma
(29.7%), with the majority having had surgery (94.6%), without
further radiotherapy (56.8%) or chemotherapy (78.4%). There
were more women (62.2%) than men (37.8%). All participants
were required to have experienced high fatigue, determined using
a cut-off above 27 on the Checklist Individual Strength (CIS).
The authors obtained ethical approval and registered the trial with
a clinical trials database. All participants gave informed consent.
The study recorded adverse events.
Intervention characteristics
Modafinil (2-benzhydrylsulfinylethanamide) is awakefulness-pro-
moting drug that targets fatigue, cognitive functioning and mood.
The study used a dose escalation, washout and cross-over method
for both arms and participants received either modafinil then
placebo or placebo then modafinil. It included a dose reduc-
tion and withdrawal technique if participants experienced adverse
events.
Primary and secondary outcomes
The study assessed the primary outcome measure of fatigue using
the CIS. It included secondary subjective measures of depression,
health-related quality of life and everyday cognitive functioning.
Cognitive functioningwas assessed using a neuropsychological test
battery to assess verbal memory, working memory, attention, exec-
utive function and psychomotor speed. Assessments were carried
out at baseline, six weeks and 12 weeks.
Data collection
The study used a cross-over trial design, therefore they collected
data for each participant on completion of the modafinil and
placebo treatment schedules. Of 155 eligible participants, 39 par-
ticipants met the inclusion criteria and agreed to participate. Two
participants dropped out prior to randomisation leaving 37 partic-
ipants in the trial, of whom 25 completed both treatment sched-
ules and had all outcomes measured. Imputation was carried out
for missing values for those who completed questionnaires and
neuropsychological assessments.
Statistical analyses
The trial used a within-participants design to determine dif-
ferences between modafinil and placebo test scores. It used a
Wilcoxon signed-rank tests as no data were normally distributed.
No corrections were carried out to account for multiple statistical
testing.
Excluded studies
For detailed information see Characteristics of excluded studies
table.
We found eight studies that included fatigue as a primary or sec-
ondary outcome measure, but we excluded them as high fatigue
was not a necessary inclusion criterion for participation. Three
studies investigated an intervention in people with brain tumours
undergoing radiotherapy (Butler 2007; Lee 2014; Shaw 2015).
Five studies evaluated an intervention in people with brain tu-
mours not on active treatment (Gehring 2009; Gehring 2012;
Kaleita 2006; Locke 2008; Shaw 2006).
Studies of people undergoing radiotherapy
Butler and co-authors evaluated the
use of d-threo-methylphenidate hydrochloride in a double-blind
randomised placebo-controlled clinical trial in people with pri-
mary metastatic brain tumours receiving radiotherapy. Participa-
tion was not limited to people with fatigue. The study enrolled 68
participants. Using the Functional Assessment of Cancer Therapy
- Fatigue sub scale (FACT-F), there were no differences between
groups in measures of fatigue eight weeks after the completion of
radiotherapy (P value = 0.64) (Butler 2007).
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Lee and co-authors presented an update of their randomised,
placebo-controlled pilot trial of armodafinil at the 2014 ASCO
annual conference, which included 77 people undergoing radio-
therapy. Participation was not limited to people with fatigue. This
ongoing study included measures of fatigue, mood and quality of
life. There were significant improvements in fatigue at 42 days
using the Brief Fatigue Inventory (Wilcoxon P value = 0.008) (Lee
2014).
Shaw and co-authors conducted a double-blind placebo-con-
trolled study of armodafinil on fatigue in people undergoing cra-
nial irradiation. Fatigue was not a necessary inclusion criterion.
The study enrolled 54 participants, andmeasured fatigue and day-
time sleepiness. There were no significant differences in outcome
measures between groups at the end of radiotherapy or at a four-
week follow-up compared to baseline. However, in a post-hoc
analysis, there was an improvement in fatigue in participants with
higher baseline fatigue, asmeasured by the FACIT-F (Shaw 2015).
Studies of people not on active tumour treatment
Gehring and co-authors investigated the use of a cognitive rehabil-
itation programme in people with glioma in a randomised wait-list
controlled trial. Participation was restricted to people with subjec-
tive and objective cognitive deficits, rather than fatigue. The study
enrolled 140 adults, and measured cognition, fatigue, quality of
life and community integration. Using the Multidimensional Fa-
tigue Inventory, people in the intervention arm reported lower
mental fatigue at six months (P value = 0.026), compared to base-
line, but not activity (P value = 0.82) or motivation (P value =
0.063) (Gehring 2009).
Gehring and co-authors enrolled 24 people with brain tumours in
an open-label randomised pilot trial comparing methylphenidate
and modafinil. Participation was not limited to people with fa-
tigue. The primary outcome measure was cognitive function.
Other outcome measures included fatigue, sleep disturbance,
mood and quality of life. In a post-hoc analysis that combined the
treatment groups, there was a beneficial effect on fatigue at four
weeks (P value = 0.04) compared to baseline, as measured using
the Brief Fatigue Inventory (Gehring 2012).
Kaleita and co-authors conducted a double-blind randomised
dose-controlled trial of modafinil on cognition, mood and fatigue
in people with brain tumours. The study did not restrict par-
ticipation to people with fatigue. There were 30 participants in
the study. There were improvements in fatigue, using the Fatigue
Severity Scale, at eight (P value = <0.0001) and 12 weeks (P value
= 0.0003) after modafinil initiation compared to baseline (Kaleita
2006).
Locke and co-authors reported the feasibility of a cognitive re-
habilitation and problem-solving programme in 19 people with
PBT. Participation was not restricted to people with fatigue. The
study included measures of fatigue, cognition, mood and quality
of life. The study used the Brief Fatigue Inventory to assess fatigue.
There were no statistical analyses, but most participants in both
groups had only mild fatigue (Locke 2008).
Shaw and co-authors evaluated 24 people with a brain tumour en-
rolled to a single-arm open-label study of donepezil. Participation
was not limited to people with fatigue. The study recorded cogni-
tion, mood, fatigue and quality of life. There was an improvement
in fatigue at 24 weeks using the Profile of Mood States Fatigue
Subscale (P value = 0.03) (Shaw 2006).
Risk of bias in included studies
Three review authors (JD, SYK, DC) independently assessed the
included trial using the Cochrane ’Risk of bias’ tool (Higgins
2011). Where risk of bias was unclear, we contacted the author
for clarification. Following discussion, we reached agreement on
’Risk of bias’ scores. Figure 2 shows the risk of bias summary.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
The trial was at a low risk of bias, using a pharmacy randomisation
system to allocate participants to each treatment arm. This was
confirmed via correspondence to be through the use of a computer
randomisation system.
Blinding
The trial was at a low risk of bias. Participants, treating physicians
and researchers were blind to treatment allocation.
Incomplete outcome data
The trial was at an unclear risk of bias. The study reported that
12 participants dropped out: a similar number of participants
dropped out between time-point 1 and 2 (Modafinil arm; n = 4,
placebo arm; n = 3); more participants dropped out of the placebo
arm (n = 4) than the modafinil arm (n = 1) between time-point 2
and 3. It was unclear why participants dropped out of each group,
therefore we contacted the author for correspondence to request
clarification. Five participants dropped out of the trial due to ad-
verse events while receiving modafinil; three participants received
modafinil first, two participants received modafinil second. Two
participants dropped out of the trial due to adverse events while
receiving placebo. The study usedmean imputation wheremissing
values were present in attempted questionnaires or neuropsycho-
logical assessments. They did not carry out an analysis to deter-
mine whether imputation or missing data could have altered the
results of the study.
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Selective reporting
The trial was at a low risk of bias; all outcomes appear to have
been reported.
Other potential sources of bias
We did not identify any additional sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Modafinil
compared with placebo for fatigue in people with a primary brain
tumour
We found one eligible trial that investigated the use of modafinil
in treating fatigue in people with PBT compared with a placebo
intervention (Boele 2013).
Primary outcome
Fatigue at study endpoint
There was no significant difference in fatigue measures between
modafinil and placebo score for concentration problems (MD -
1.06, 95% CI -3.18 to 1.06), reduced motivation (MD -0.48,
95% CI -2.93 to 1.97), reduced activity (MD -1.01, 95% CI -
5.64 to 3.62) or fatigue severity (MD -0.22, 95% CI -0.79 to
0.35) (Analysis 1.1).
Secondary outcomes
Cognitive functioning
A significant difference was found between modafinil and placebo
scores in attentional functioning (MD -0.03, 95% CI -0.05 to -
0.01). There were no significant differences in objective cognitive
functioning (verbal memory, MD 0.26, 95% CI -0.05 to 0.57;
working memory, MD 0.07, 95% CI -0.04 to 0.18; information
processing, MD 0.17, 95% CI -1.19 to 1.53; executive function,
MD 0.14, 95% CI -9.33 to 9.61; psychomotor speed, MD 0.10,
95% CI -0.26 to 0.46) (Analysis 1.2), subjective cognitive func-
tioning (MD 1.62, 95% CI -0.74 to 3.98) (Analysis 1.3), depres-
sion (MD 0.19, 95% CI -1.33 to 1.71) (Analysis 1.4) or quality
of life (physical, MD 1.34, 95% CI -20.11 to 22.79; mental, MD
-1.40, 95% CI -4.84 to 2.04) (Analysis 1.5).
Adverse events
Reported adverse events included tingling sensations, depressive
feelings or behaviours, nervousness, dizziness, vertigo, headaches,
loss of appetite and seizures. Five participants dropped out of the
trial due to adverse events while receiving modafinil; two partici-
pants dropped out of the trial due to adverse events while receiv-
ing placebo. There was no difference in adverse events reported
between groups (RR 2.79, 95% CI 0.59 to 13.16) (Analysis 1.6).
D I S C U S S I O N
The aim of this review was to determine the effectiveness of in-
terventions to treat high fatigue in people with PBT. We included
one randomised controlled cross-over trial comparing the effect of
modafinil to placebo (Boele 2013).
Summary of main results
Boele 2013 recruited 37 participants and used a cross-over design
to compare modafinil and placebo across three centres in The
Netherlands. The washout period between treatments was one
week. Since the half-life ofmodafinil is 10 to 12 hours, the washout
period was likely adequate. There was no significant difference in
fatigue between modafinil and placebo groups. This finding was
difficult to interpret because the trial failed to reach its recruitment
target andmay have lacked power to exclude a false-negative result.
There were improvements in fatigue severity and motivation in
both modafinil and placebo conditions compared with baseline.
Overall completeness and applicability of
evidence
We could only include one RCT examining the effectiveness of an
intervention to treat fatigue in adults with PBT. The trial included
people with glioma and meningioma tumours and, therefore, may
be representative across these brain tumour types. All participants
were fatigued at baseline and, therefore, results could potentially
generalise to people with fatigue. However, since this trial had low
accrual and high attrition, and restricted follow-up to 12 weeks,
overall the applicability of the evidence was limited.
We excluded eight studies that reported fatigue outcomes, but
which enrolled a general population of people with brain tumours
rather than restricting eligibility to people who were highly fa-
tigued. We excluded these studies in order that our conclusions
could be readily applied to a clinically relevant problem. However,
we recognised that the excluded studies contained valuable data.
More research is needed into whether the interventions investi-
gated specifically benefit highly fatigued people with PBT, who
are the ones most likely to require treatment in clinic.
Quality of the evidence
See Figure 2.
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This review summarised the current evidence for the effect of
pharmacological and non-pharmacological interventions for the
treatment of fatigue in adults with PBT. There was only one trial
eligible for inclusion in the review. The included trial was at a
low risk of bias across most areas, with an unclear risk of bias
with respect to incomplete outcome data. Low accrual and high
attrition limited the generalisability of this trial and taken together,
the overall quality of evidence is currently low.
Potential biases in the review process
We searched five databases extensively, which included published
studies and the most recent conference proceedings. We also
searched the reference list of the included trial. Though we thor-
oughly handsearched the literature and searched online databases
for unpublished and grey literature, and contacted known experts
in the field to determine any further unpublished studies that may
be eligible, we may have nevertheless failed to identify all eligible
studies, specifically those that have not been published.
Agreements and disagreements with other
studies or reviews
Authors of two narrative reviews on this topic also highlighted
the lack of high-quality evidence for treatment, noting favourable
effectiveness of interventions in the general cancer population (
Armstrong 2012; Schiff 2014).
We found one ongoing Phase III double-blind placebo-controlled
RCT using armodafinil for the treatment of fatigue in people with
high-grade gliomas that aims to include only people with fatigue
(Umphrey 2013). This study will hopefully offer more evidence
for inclusion in a future update.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, the effectiveness of any treatment for high fatigue in
people with primary brain tumours is unclear. As detailed above
only one trial met our pre-defined inclusion criteria with 37 par-
ticipants. This limits the conclusions that can be drawn. Other
trials enrolling a general population of people with brain tumour
suggest a potential benefit of certain treatments, but these data are
difficult to generalise to clinical practice and require further study.
In the wider cancer field, one Cochrane review about drug ther-
apy for the management of cancer-related fatigue estimated the
effect of several drugs including psychostimulants, hematopoietic
growth factors, antidepressants and progestational steroids. Psy-
chostimulants showed a small but significant improvement in fa-
tigue over placebo (Z = 2.83; P value < 0.01). The conclusions
were based on small samples (Minton 2010). The differences in
the results from this review may be due to the inclusion of only
people with PBT, that only one study met our pre-defined inclu-
sion criteria and that modafinil was not one of the drugs included
in the cancer-related review. The widely used National Compre-
hensive Cancer Network (NCCN) guidelines recommend iden-
tifying treatable contributory factors including sleep disturbance,
anaemia, pain, emotional distress, nutritional deficiencies, poor
functional status, medication and co-morbidities (NCCN 2014).
Given the relative lack of solid evidence, if a person with PBT
and fatigue starts pharmacological treatment for fatigue, it may be
advisable to use close follow-up to help detect and manage adverse
effects.
Implications for research
Randomised controlled trials are necessary to address the benefits
and risks of using pharmacological and non-pharmacological in-
terventions. These should be appropriately powered. Important
research questions may include whether any intervention focusing
on decreasing fatigue in people with primary brain tumours:
• is effective in treating high fatigue;
• has clinically significant effects on depression and cognition;
• has clinically significant pharmacokinetic interactions with
tumour-related treatment (antiepileptic drugs, chemotherapy);
• has a clinically significant effect on survival.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boele 2013
Methods Double-blind randomised placebo-controlled trial, parallel arm
Participants Inclusion criteria: aged ≥ 18 years; diagnosed with a histologically confirmed glioma
or meningioma; no signs of tumour recurrence in the last 6 months; fatigue self reported
> 27 on the Checklist Individual Strength
Exclusion criteria: history of psychiatric disease or symptoms; expected adverse interac-
tions between prescribed medications and modafinil; unable to communicate in Dutch
Number randomised: modafinil: 20; placebo: 17
Follow-up: 12 weeks
Setting: 3 centres in The Netherlands
Interventions 2 treatment arms of 6 weeks
Arm 1 treatment schedule:
Week 1: oral modafinil 200 mg per day taken in divided does (100 mg upon waking,
100 mg at lunch)
Week 2-6: oral modafinil 400 mg per day taken in divided doses (200 mg upon waking,
200 mg at lunch)
Week 7: washout period
Week 8-12: matched placebo
Arm 2 treatment schedule:
Week 1-6: matched placebo
Week 7: washout period
Week 8: oral modafinil 200 mg per day taken in divided does (100 mg upon waking,
100 mg at lunch)
Week 9-12: oral modafinil 400 mg per day taken in divided doses (200 mg upon waking,
200 mg at lunch)
Outcomes Fatigue (Checklist Individual Strength)
Depression (Center for Epidemiologic Studies Depression Scale)
Health-related quality of life (Medical Outcomes Study Short-Form Health Survey)
Subjective cognitive functioning (Medical Outcomes Study subjective cognitive func-
tioning scale)
Objective cognitive functioning (Rey Auditory Verbal Learning Test, Memory Compar-
ison Test, Stroop Colour Word Test, Letter Digit Substitution Test, Concept Shifting
Test, Categorical Word Fluency Test, Concept Shifting Test)
Notes Mean imputation used where missing values were present in questionnaires or neuropsy-
chological assessments
No corrections for multiple statistical testing carried out
Risk of bias
Bias Authors’ judgement Support for judgement
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Boele 2013 (Continued)
Random sequence generation (selection
bias)
Low risk “A pharmacy randomization system was
used to assign participants”. Confirmed via
correspondence
Allocation concealment (selection bias) Low risk “A pharmacy randomization system was
used to assign participants”. Confirmed via
correspondence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients, treating physicians, and re-
searchers were blind to treatment alloca-
tion”. Confirmed via correspondence
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients, treating physicians, and re-
searchers were blind to treatment alloca-
tion”. Confirmed via correspondence
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how much imputation may have
affected the result as sensitivity analysis was
not carried out to determine whether miss-
ing data altered the results of the review
Similar number of participants dropped
out between time points 1 and 2 (modafinil
arm; n = 4, placebo arm; n = 3), more par-
ticipants dropped out of placebo arm (n
= 4) than modafinil arm (n = 1) between
time points 2 and 3. Mean imputation
was used where missing values were present
in questionnaires or neuropsychological as-
sessments. Details of adverse events per
group confirmed through correspondence
with the lead author
Five participants dropped out of the trial
due to adverse events while receiving
modafinil. Details per participant were:
• tingling sensations, depressive
feelings, feeling nervous/fidgety, dizziness
• depressive feelings, crying without a
clear cause
• vertigo, feeling as if about to get a
seizure, ’light feeling’ in head
• increased headaches, feeling nervous,
tingling sensations, feeling anxious
• reduced appetite, nausea, sometimes
vomiting, stuffy feeling in head, feeling
fidgety
Two participants dropped out of the trial
due to adverse events while receiving
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Boele 2013 (Continued)
placebo. Details per participant were:
• vertigo, nausea
• seizures, fatigue
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Butler 2007 Fatigue was not a necessary inclusion criterion
Gehring 2009 Fatigue was not a necessary inclusion criterion
Gehring 2012 Fatigue was not a necessary inclusion criterion
Kaleita 2006 Fatigue was not a necessary inclusion criterion
Lee 2014 Fatigue was not a necessary inclusion criterion
Locke 2008 Fatigue was not a necessary inclusion criterion
Shaw 2006 Fatigue was not a necessary inclusion criterion. No control group
Shaw 2015 Fatigue was not a necessary inclusion criterion
Characteristics of ongoing studies [ordered by study ID]
Umphrey 2013
Trial name or title Armodafinil in Reducing Cancer-Related Fatigue in Patients with High Grade Glioma
Methods Phase III double-blind placebo-controlled randomised controlled trial. Participants were randomly assigned
to receive one of two doses of armodafinil or placebo for 8 weeks
Participants Inclusion criteria: aged≥ 18 years; glioblastoma multiforme, anaplastic astrocytoma, gliosarcoma or anaplas-
tic oligodendroglioma; clinically stable (stable/improved Karnofsky Performance Status compared to the prior
month); completed radiotherapy > 21 days and ≤ 24 months prior to enrolment; ≥ 6 score on the worst
fatigue question of the Brief Fatigue Inventory; previous surgery (gross total or sub-total resection) or biopsy;
negative serum pregnancy test done ≤ 7 days prior to registration; ability to complete questionnaire(s) by
themselves or with assistance, Eastern Cooperative Oncology Group Performance Status 0, 1, 2 or 3; provide
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Umphrey 2013 (Continued)
informed written consent; willing to return to enrolling institution for follow-up (during the active monitor-
ing phase of the study); stable dose of corticosteroid ≤ 28 days prior to registration
Exclusion criteria: history of hypersensitivity to other psychostimulants; history of steroid psychosis; history
of/currently takingmedications for attention deficit hyperactivity disorder, severe anxiety disorder, schizophre-
nia or substance abuse by patient record or self report, or both; currently taking medications to treat fatigue
including psychostimulants, antidepressants, acupuncture (antidepressants used to treat items other than fa-
tigue (such as hot flushes or depression) were allowed if the person had been on a stable dose for≥ 30 days and
planned to continue for the duration of the trial); anticipating surgery; laboratory evidence of hypothyroidism
with an elevated thyroid-stimulating hormone concentration in the blood > 5.0 mlU/L; profound anaemia
(haemoglobin < 10 g/dL) ≤ 28 days prior to registration; clinical depression per physician discretion; active/
history of Tourette’s syndrome or tic disorder, glaucoma, intractable epilepsy or uncontrolled seizure disor-
der; history of myocardial infarction, unstable angina, left ventricular hypertrophy or mitral valve prolapse
syndrome; use of strong or moderate inhibitors of cytochrome P450 3A4 ≤ 7 days prior to registration; use
of medications or substances that are inducers of cytochrome P450 3A4 ≤ 7 days prior to registration
Follow-up: 8 weeks
Setting: 92 centres in the USA
Interventions Arm 1: armodafinil 150 mg
Arm 2: armodafinil 250 mg
Arm 3: matched placebo
Outcomes Participant-reported fatigue (Brief Fatigue Inventory)
Patient-Reported Outcomes Measurement Information System
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
Cognitive functioning (Symbol Digit Modalities Test, Controlled Oral Word Association, Trail Making Test,
Functional Assessment of Cancer Therapy - Cognitive Function)
Quality of life (linear analogue self assessment)
Starting date 2013
Contact information Study Chair:
Alyx Umphrey
Mayo Clinic
Rochester
Minnesota
MN 55905
USA
+1 507 538 7623
Notes ClinicalTrials.gov Identifier: NCT01781468
Current status: recruiting participants as of November 2015
IU: international units.
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D A T A A N D A N A L Y S E S
Comparison 1. Modafinil versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fatigue 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Concentration problems 1 55 Mean Difference (IV, Fixed, 95% CI) -1.06 [-3.18, 1.06]
1.2 Reduced motivation 1 55 Mean Difference (IV, Fixed, 95% CI) -0.48 [-2.93, 1.97]
1.3 Reduced activity 1 55 Mean Difference (IV, Fixed, 95% CI) -1.01 [-5.64, 3.62]
1.4 Fatigue severity 1 55 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.79, 0.35]
2 Objective cognitive functioning 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Verbal memory 1 53 Mean Difference (IV, Fixed, 95% CI) 0.26 [-0.05, 0.57]
2.2 Working memory 1 53 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.04, 0.18]
2.3 Attentional functioning 1 53 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.05, -0.01]
2.4 Information processing 1 53 Mean Difference (IV, Fixed, 95% CI) 0.17 [-1.19, 1.53]
2.5 Executive functioning 1 53 Mean Difference (IV, Fixed, 95% CI) 0.14 [-9.33, 9.61]
2.6 Psychomotor speed 1 53 Mean Difference (IV, Fixed, 95% CI) 0.1 [-0.26, 0.46]
3 Subjective cognitive functioning 1 55 Mean Difference (IV, Fixed, 95% CI) 1.62 [-0.74, 3.98]
4 Depression 1 55 Mean Difference (IV, Fixed, 95% CI) 0.19 [-1.33, 1.71]
5 Health-related quality of life 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Physical 1 55 Mean Difference (IV, Fixed, 95% CI) 1.34 [-20.11, 22.79]
5.2 Mental 1 55 Mean Difference (IV, Fixed, 95% CI) -1.40 [-4.84, 2.04]
6 Adverse events 1 55 Risk Ratio (M-H, Fixed, 95% CI) 2.79 [0.59, 13.16]
WH A T ’ S N E W
Last assessed as up-to-date: 2 March 2016.
Date Event Description
9 June 2016 Amended Author contact details updated
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Obtain copies of trials JD, SYK, DC
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Extract data from trials (3 people) JD, SYK, DC
Enter data into Revview Manager 5 JD, SYK, DC
Carry out the analysis JD, SYK, DC
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For clarification, we changed the following sentence “We include details of missing data in the narrative summary and ’Risk of bias’
table, alongside an assessment of the extent to which the missing data could have altered the results of the review” in the protocol,
to “We included details of missing data in the narrative summary and ’Risk of bias’ table, and stated whether authors examined the
extent to which the missing data could have altered the results of the review” in the full review. This was to clarify that we had not
planned to carry out any formal analyses but to assess the extent to which the missing data could have altered the results by reviewing
any assessments carried out by the included studies.
N O T E S
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I N D E X T E R M S
Medical Subject Headings (MeSH)
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